The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Santarus's revenues will grow 75.7% and EPS will grow 260.0%.
The average estimate for revenue is $82.9 million. On the bottom line, the average EPS estimate is $0.18.
Last quarter, Santarus booked revenue of $79.4 million. GAAP reported sales were 73% higher than the prior-year quarter's $45.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, EPS came in at $0.25. GAAP EPS of $0.25 for Q1 were much higher than the prior-year quarter's $0.01 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 72.3%, much better than the prior-year quarter. Operating margin was 25.3%, much better than the prior-year quarter. Net margin was 23.6%, much better than the prior-year quarter.
The full year's average estimate for revenue is $345.7 million. The average EPS estimate is $0.95.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 179 members out of 193 rating the stock outperform, and 14 members rating it underperform. Among 54 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 51 give Santarus a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Santarus is outperform, with an average price target of $16.80.
- Add Santarus to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why You Need To Watch Johnson & Johnson, The Medicines Company, Santarus, and Tesaro Today
Johnson & Johnson, The Medicines Company, Santarus, and Tesaro could loom large in health care headlines this morning. Here’s why.
Everyone Wins With This Biotech Buyout
This biotech buyout sent shares of both companies soaring. Should investors be jumping in?
Will These 3 Biotechs Continue to Rally This Week?
Nektar Therapeutics and Salix look like biotechs to look closer at, while Santarus seems like it's hit a wall.